| scholarly article | Q13442814 |
| P2093 | author name string | James P Hamilton | |
| Stefan David | |||
| P2860 | cites work | Acute cholestatic hepatitis induced by glimepiride | Q43524948 |
| The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury | Q43539187 | ||
| Fulminant exacerbation of autoimmune hepatitis after the use of ma huang | Q43618430 | ||
| Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy | Q43653505 | ||
| Mechanism of azathioprine-induced injury to hepatocytes: roles of glutathione depletion and mitochondrial injury | Q43818672 | ||
| Autoantibodies associated with volatile anesthetic hepatitis found in the sera of a large cohort of pediatric anesthesiologists | Q43867427 | ||
| Pioglitazone-associated fulminant hepatic failure | Q43897279 | ||
| Severe hepatotoxicity associated with the dietary supplement LipoKinetix | Q43960354 | ||
| Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients | Q44110151 | ||
| HLA and drug-induced toxicity. | Q44185306 | ||
| A cohort study of nevirapine tolerance in clinical practice: French Aquitaine Cohort, 1997-1999. | Q44200937 | ||
| Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia | Q44210740 | ||
| A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. | Q44269062 | ||
| Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts. | Q44340780 | ||
| A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents | Q44363470 | ||
| Troglitazone-induced liver failure: a case study | Q44394235 | ||
| Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis | Q44452635 | ||
| Autoimmune hepatitis revealed by atorvastatin | Q44516447 | ||
| High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure | Q44545437 | ||
| Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment | Q44605409 | ||
| Syntheses and characterization of the acyl glucuronide and hydroxy metabolites of diclofenac | Q44893603 | ||
| Glimepiride-induced cute cholestatic hepatitis | Q44973627 | ||
| Second-generation thiazolidinediones and hepatotoxicity | Q44987602 | ||
| Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir | Q45172156 | ||
| Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid | Q45175722 | ||
| The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity. | Q45214493 | ||
| Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects | Q45270618 | ||
| Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus | Q45488266 | ||
| Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection | Q45739024 | ||
| Rifampin hepatotoxicity associated with treatment of latent tuberculosis infection | Q46084148 | ||
| Incidence of statin hepatotoxicity in patients with hepatitis C. | Q46306911 | ||
| Nimesulide associated fulminant hepatic failure. | Q46343326 | ||
| Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy | Q46430597 | ||
| Rosuvastatin-associated hepatitis with autoimmune features | Q46435413 | ||
| Cholestatic liver injury after glimepiride therapy | Q46483268 | ||
| Hepatotoxicity of pyrazinamide: cohort and case-control analyses | Q46664625 | ||
| High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis | Q46665807 | ||
| Risk of side effects associated with the use of nevirapine in treatment-naïve patients, with respect to gender and CD4 cell count. | Q46805408 | ||
| HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease | Q47375273 | ||
| Biotransformation of halothane, enflurane, isoflurane, and desflurane to trifluoroacetylated liver proteins: association between protein acylation and hepatic injury. | Q51554373 | ||
| Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. | Q51635879 | ||
| Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. | Q51769708 | ||
| Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during antituberculosis [correction of antituberclosis] treatment. | Q51979264 | ||
| Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. | Q53249151 | ||
| Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. | Q53329945 | ||
| Rifampin preventive therapy for tuberculosis in Boston's homeless. | Q54377208 | ||
| Hepatitis associated with terbinafine therapy: three case reports and a review of the literature | Q58404841 | ||
| Comparison of two clinical scales for causality assessment in hepatotoxicity | Q60344692 | ||
| Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin | Q64133815 | ||
| Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents | Q64133863 | ||
| Hepatotoxicity of anti-inflammatory and analgesic drugs: ultrastructural aspects | Q28195255 | ||
| Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia | Q28214395 | ||
| Early indicators of prognosis in fulminant hepatic failure | Q28241473 | ||
| Prolonged cholestasis due to trimethoprim sulfamethoxazole | Q28319863 | ||
| Nitrofurantoin-induced chronic liver disease. Clinical course and outcome of five cases | Q28327963 | ||
| The human bile salt export pump: characterization of substrate specificity and identification of inhibitors | Q28612066 | ||
| HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin | Q29417159 | ||
| Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis | Q33889576 | ||
| Acetaminophen poisoning and toxicity | Q33946394 | ||
| Mechanism of indinavir-induced hyperbilirubinemia | Q33947992 | ||
| Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. | Q34088490 | ||
| Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir | Q34117815 | ||
| Acute versus chronic alcohol consumption in acetaminophen-induced hepatotoxicity | Q34120596 | ||
| Cascara sagrada-induced intrahepatic cholestasis causing portal hypertension: case report and review of herbal hepatotoxicity | Q34127332 | ||
| Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States | Q34165115 | ||
| Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases | Q34176531 | ||
| The efficacy and safety of comfrey. | Q34199778 | ||
| Drug-induced cholestasis | Q34250537 | ||
| Criteria of drug-induced liver disorders. Report of an international consensus meeting | Q34271897 | ||
| Hepatotoxicity of antibiotics. | Q34289694 | ||
| Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure | Q34303815 | ||
| The role of metabolic activation in drug-induced hepatotoxicity | Q34410432 | ||
| Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period | Q34440712 | ||
| Acute hepatitis induced by greater celandine (Chelidonium majus). | Q34505490 | ||
| Statin safety: a systematic review | Q34566154 | ||
| Severe hepatic side effects of ezetimibe | Q34568608 | ||
| An official ATS statement: hepatotoxicity of antituberculosis therapy | Q34571651 | ||
| Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus | Q34593097 | ||
| How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial | Q34603723 | ||
| Herbal does not mean innocuous: ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife products | Q34662084 | ||
| The liver and lovastatin | Q34683472 | ||
| Liver injuries induced by herbal medicine, syo-saiko-to (xiao-chai-hu-tang). | Q34721069 | ||
| Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. | Q39633214 | ||
| Acetaminophen hepatotoxicity in alcoholics. A therapeutic misadventure | Q39727500 | ||
| Fatal liver failure associated with pioglitazone | Q39941987 | ||
| Hepatotoxicity of Erythromycin | Q39979259 | ||
| A new prognostic formula for adult acute liver failure using computer tomography-derived hepatic volumetric analysis | Q39986739 | ||
| Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity | Q40379756 | ||
| Cholestatic hepatitis with severe systemic reactions induced by trimethoprim-sulfamethoxazole. | Q40457914 | ||
| Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts | Q40518038 | ||
| Successful orthotopic liver transplantation after trimethoprim-sulfamethoxazole associated fulminant liver failure | Q40542803 | ||
| Acute hepatitis associated with the Chinese herbal product jin bu huan | Q40693951 | ||
| Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries | Q40775438 | ||
| Ketoconazole-associated hepatic injury. A clinicopathological study of 55 cases | Q40812137 | ||
| Cholestatic and hepatocellular injury associated with erythromycin esters: report of nine cases | Q40868753 | ||
| Nafcillin-associated hepatotoxicity. Report of a case and review of the literature | Q40948715 | ||
| Acute hepatitis associated with the use of a Chinese herbal product, ma-huang. | Q41013799 | ||
| Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis | Q41115305 | ||
| The complex interaction between ethanol and acetaminophen | Q41139387 | ||
| Cytochrome P450 2E1 is a cell surface autoantigen in halothane hepatitis. | Q41172302 | ||
| Autoimmune hepatitis triggered by administration of an herbal medicine. | Q41452637 | ||
| Immunoallergic drug-induced hepatitis: lessons from halothane | Q41460544 | ||
| Sulindac hepatotoxicity: effects of acute and chronic exposure | Q42224712 | ||
| Halothane-induced acute liver failure: continuing occurrence and use of liver transplantation | Q42539578 | ||
| Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study | Q42551688 | ||
| Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis. | Q42552705 | ||
| Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid | Q42556086 | ||
| Terbinafine-induced hepatic failure requiring liver transplantation | Q42607592 | ||
| Liver transplantation for acute liver failure from drug induced liver injury in the United States | Q42636770 | ||
| Resolution of hepatitis C virus-induced steatosis improves tolerability of antiretroviral drugs associated with hepatotoxicity in an HIV-infected individual | Q42977798 | ||
| Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients | Q43039722 | ||
| Drug-induced liver injury: is it somehow foreseeable? | Q43109156 | ||
| Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events | Q43259278 | ||
| Hepatitis after germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity | Q43491033 | ||
| Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases | Q43505355 | ||
| [Hepatitis observed during a treatment with a drug or tea containing Wild Germander. Evaluation of 26 cases reported to the Regional Centers of Pharmacovigilance] | Q68003208 | ||
| Acute hepatitis caused by wild germander. Hepatotoxicity of herbal remedies. Two cases | Q68059810 | ||
| Sulfonamide-induced chronic liver disease | Q68882988 | ||
| Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin | Q69536937 | ||
| Sulindac-associated hepatic injury: analysis of 91 cases reported to the Food and Drug Administration | Q70542333 | ||
| Erythromycin-associated cholestatic hepatitis | Q70673726 | ||
| The clinical spectrum of Jin Bu Huan toxicity | Q71446209 | ||
| Uncoupling of rat and human mitochondria: a possible explanation for tacrine-induced liver dysfunction | Q71884859 | ||
| Drug-induced cholestasis | Q73312574 | ||
| Hepatic failure in a patient taking rosiglitazone | Q73375979 | ||
| Hepatocellular injury in a patient receiving rosiglitazone. A case report | Q73375988 | ||
| Acute hepatitis induced by Greater Celandine (Chelidonium majus) | Q73499637 | ||
| Hepatitis induced by Kava (Piper methysticum rhizoma) | Q73561725 | ||
| Drug-induced cholestasis | Q73706026 | ||
| Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis | Q73712041 | ||
| [Hepatotoxicity caused by cloxacillin] | Q73712325 | ||
| Chronic hepatitis induced by Jin Bu Huan | Q74429559 | ||
| Metabolic activation of diclofenac by human cytochrome P450 3A4: role of 5-hydroxydiclofenac | Q74459687 | ||
| Ketoconazole-induced liver damage | Q77127652 | ||
| Spirulina-associated hepatotoxicity | Q78690386 | ||
| Understanding the role of reactive metabolites in drug-induced hepatotoxicity: state of the science | Q79701054 | ||
| MELD score as a predictor of liver failure and death in patients with acetaminophen-induced liver injury | Q79839962 | ||
| Drug- and chemical-induced cholestasis | Q79866237 | ||
| Isolation and characterisation of selected germander diterpenoids from authenticated Teucrium chamaedrys and T. canadense by HPLC, HPLC-mS and NMR | Q80115225 | ||
| Antituberculous therapy-induced fulminant hepatic failure: successful treatment with liver transplantation and nonstandard antituberculous therapy | Q80168474 | ||
| Autoimmune hepatitis triggered by statins | Q80186200 | ||
| Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: a case/noncase analysis of spontaneous reports | Q80282082 | ||
| Drug-induced liver injury network (DILIN) | Q80594548 | ||
| Herbal hepatotoxicity | Q80853381 | ||
| Herbal hepatotoxicity | Q81235309 | ||
| Hepatotoxicity of antiretrovirals: incidence, mechanisms and management | Q81644444 | ||
| Acute hepatitis induced by Chinese hepatoprotective herb, xiao-chai-hu-tang | Q82999297 | ||
| An assessment of statin safety by hepatologists | Q83040428 | ||
| Oxidative stress and alcoholic liver disease | Q83707371 | ||
| Toxic hepatitis with isoniazid and rifampin. A meta-analysis | Q34745978 | ||
| Severe hepatotoxicity following ingestion of Herbalife nutritional supplements contaminated with Bacillus subtilis. | Q34880762 | ||
| Immune-mediated drug-induced liver disease | Q34936720 | ||
| Co-amoxiclav jaundice: clinical and histological features and HLA class II association. | Q35361803 | ||
| Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors | Q35676417 | ||
| A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs | Q36053665 | ||
| Liver enzymes elevation after HAART in HIV-HCV co-infection | Q36177726 | ||
| Acute liver failure due to amoxicillin and amoxicillin/clavulanate | Q36269276 | ||
| Drug withdrawals and the lessons within. | Q36381113 | ||
| Mechanisms of drug-induced liver injury. | Q36439183 | ||
| Chemotherapy-induced sclerosing cholangitis: long-term response to endoscopic therapy | Q36457586 | ||
| Pyrimidine nucleoside depletion sensitizes to the mitochondrial hepatotoxicity of the reverse transcriptase inhibitor stavudine | Q36482233 | ||
| Chemotherapy-induced sclerosing cholangitis | Q36537370 | ||
| Safety issues with statin therapy | Q36567630 | ||
| Antiretroviral medication considerations for individuals coinfected with HIV and hepatitis C virus | Q36628547 | ||
| Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury | Q36725202 | ||
| Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct | Q36799781 | ||
| Effectiveness and hepatotoxicity of statins in men seropositive for hepatitis C virus | Q36837171 | ||
| Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States | Q36844723 | ||
| Nonsteroidal anti-inflammatory drug-induced hepatotoxicity | Q36920992 | ||
| Antituberculosis drug-induced hepatotoxicity: concise up-to-date review | Q36998032 | ||
| Viral hepatitis and HIV coinfection | Q37043908 | ||
| Risk for immune-mediated liver reactions by nevirapine revisited. | Q37211741 | ||
| Review article: The use of potentially hepatotoxic drugs in patients with liver disease | Q37232075 | ||
| Flucloxacillin-induced liver injury. | Q37269762 | ||
| Practical guidelines for diagnosis and early management of drug-induced liver injury | Q37341906 | ||
| Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials | Q37367505 | ||
| Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection | Q38858952 | ||
| Chaparral ingestion. The broadening spectrum of liver injury caused by herbal medications | Q39029125 | ||
| Short screening scales to monitor population prevalences and trends in non-specific psychological distress | Q39513016 | ||
| Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection | Q39526550 | ||
| Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients | Q39530519 | ||
| Incidence of drug-induced hepatic injuries: a French population-based study | Q39609276 | ||
| P304 | page(s) | 73-80 | |
| P577 | publication date | 2010-01-01 | |
| P1433 | published in | US gastroenterology & hepatology review | Q27723801 |
| P1476 | title | Drug-induced Liver Injury | |
| P478 | volume | 6 |
| Q60923332 | A Turn-On Optoacoustic Probe for Imaging Metformin-Induced Upregulation of Hepatic Hydrogen Sulfide and Subsequent Liver Injury |
| Q89964249 | Development of Prediction Models for Drug-Induced Cholestasis, Cirrhosis, Hepatitis, and Steatosis Based on Drug and Drug Metabolite Structures |
| Q94503833 | Drug-Induced Liver Injury in GI Practice |
| Q55345230 | Drug-Induced Liver Injury: An Institutional Case Series and Review of Literature. |
| Q28075991 | Key Challenges and Opportunities Associated with the Use of In Vitro Models to Detect Human DILI: Integrated Risk Assessment and Mitigation Plans |
| Q26781801 | MicroRNAs in Drug-induced Liver Injury |
| Q90462172 | Mimicking of Phase I Metabolism Reactions of Molindone by HLM and Photocatalytic Methods with the Use of UHPLC-MS/MS |
| Q93140989 | Overview of drug-induced liver injury in China |
| Q64936122 | Paper supported long-term 3D liver co-culture model for the assessment of hepatotoxic drugs. |
| Q60912409 | Paradoxical Role of Matrix Metalloproteinases in Liver Injury and Regeneration after Sterile Acute Hepatic Failure |
| Q58555067 | Previous Drug Exposure in Patients Hospitalised for Acute Liver Injury: A Case-Population Study in the French National Healthcare Data System |
| Q90377129 | Progressive familial intrahepatic cholestasis type-3 and multiple sclerosis: lessons from comorbidity |
| Q88930670 | The hepatobiliary complications of malnutrition and nutritional support in adults |
Search more.